Troponin I

Global Cardiac Marker Testing Market Expected to Reach $6.9 Billion by 2028, Driven by Aging Population and Rising Cardiovascular Diseases - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023

The global cardiac marker testing market is poised for substantial growth, with projections estimating it to reach USD 6.9 billion by 2028, a significant increase from its 2022 value of USD 4.1 billion.

Key Points: 
  • The global cardiac marker testing market is poised for substantial growth, with projections estimating it to reach USD 6.9 billion by 2028, a significant increase from its 2022 value of USD 4.1 billion.
  • Aging Population: The increasing global aging population has led to a higher prevalence of cardiovascular diseases.
  • Rising Cardiovascular Diseases: Cardiovascular diseases are on the rise worldwide, making cardiac marker testing an essential tool for the diagnosis and monitoring of these conditions.
  • In 2022, laboratory testing facilities represented the largest share, accounting for 61.2% of the global cardiac marker testing market.

Cardiac Biomarkers Market is Set to Reach $26.43 Billion by 2028, Fueled by Widespread Multi-Biomarker Adoption - Arizton

Retrieved on: 
Tuesday, October 17, 2023

the global market for cardiac biomarkers can be categorized based on biomarker types, which include troponin, creatine kinase (CK-MB), myoglobin, and other biomarkers.

Key Points: 
  • the global market for cardiac biomarkers can be categorized based on biomarker types, which include troponin, creatine kinase (CK-MB), myoglobin, and other biomarkers.
  • The global market for cardiac biomarkers can be divided by end-user into hospitals, diagnostic laboratories, and other healthcare facilities.
  • Europe holds a significant share of the global cardiac biomarkers market due to the rising incidence of CVDs and an aging population.
  • In addition, government initiatives to improve healthcare facilities and reduce CVD-related morbidity and mortality further boost the adoption of cardiac biomarkers in Europe.

Cardiac Biomarkers Market is Set to Reach $26.43 Billion by 2028, Fueled by Widespread Multi-Biomarker Adoption - Arizton

Retrieved on: 
Tuesday, October 17, 2023

the global market for cardiac biomarkers can be categorized based on biomarker types, which include troponin, creatine kinase (CK-MB), myoglobin, and other biomarkers.

Key Points: 
  • the global market for cardiac biomarkers can be categorized based on biomarker types, which include troponin, creatine kinase (CK-MB), myoglobin, and other biomarkers.
  • The global market for cardiac biomarkers can be divided by end-user into hospitals, diagnostic laboratories, and other healthcare facilities.
  • Europe holds a significant share of the global cardiac biomarkers market due to the rising incidence of CVDs and an aging population.
  • In addition, government initiatives to improve healthcare facilities and reduce CVD-related morbidity and mortality further boost the adoption of cardiac biomarkers in Europe.

Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

Retrieved on: 
Wednesday, May 31, 2023

PRIME designation offers the benefits of early and enhanced support from the EMA for the development of medicines that target unmet medical needs, as well as the opportunity for an accelerated review of the marketing application.

Key Points: 
  • PRIME designation offers the benefits of early and enhanced support from the EMA for the development of medicines that target unmet medical needs, as well as the opportunity for an accelerated review of the marketing application.
  • Rocket was also recently granted Regenerative Medicine Advanced Therapy (RMAT) designation for its RP-A501 program, which also holds Fast Track , Orphan Drug (U.S.) and Rare Pediatric designations.
  • “PRIME designation from the EMA further highlights the positive benefit/risk profile of RP-A501 in addressing the critical unmet need of patients facing Danon Disease,” said Kinnari Patel, Pharm.D., MBA, President and Chief Operating Officer, Rocket Pharma.
  • The results demonstrated improvements and/or normalization across multiple quantifiable parameters that cardiologists use in clinical practice to enable risk assessment and treatment decisions.

Global Cardiac Troponin (Troponin I and Troponin T) Diagnostics Market Forecasts and Opportunities to 2025 with Abbot, Roche, and Siemens Healthineers Dominating as New Players Enter the Market - ResearchAndMarkets.com

Retrieved on: 
Friday, December 23, 2022

The "Cardiac Troponin Diagnostics - Forecasts and Opportunities to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Troponin Diagnostics - Forecasts and Opportunities to 2025" report has been added to ResearchAndMarkets.com's offering.
  • Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics.
  • In addition, companies such as QuidelOrtho and Siemens Healthineers have developed high-sensitivity POCT cTn assays that provide accurate results within a few minutes.
  • The analyst's research shows high consolidation in the cTn diagnostics market, with players such as Abbot, Roche, and Siemens Healthineers dominating.

Cardiac Marker Testing Market by Product, Component, Disease, End-user and Region - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 7, 2022

The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period.

Key Points: 
  • The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period.
  • Troponin I and T estimated held the largest share of cardiac marker testing market in 2021, by Biomarker Type
    Based on biomarker type, the cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide (BNP and Nt-proBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers.
  • The Troponin I and T segment accounted for the largest share of 51.1 % of the cardiac marker testing market in 2021.
  • In 2021, the laboratory testing facilities segment accounted for the largest share of 61.4% of the global cardiac marker testing market.

Global Cardiac Marker Analyzer Market to 2027 - Impact Analysis of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 23, 2022

The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment.

Key Points: 
  • The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment.
  • Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others.
  • The COVID-19 pandemic has restricted the growth of the Cardiac Marker Analyzer market, by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic.
  • In the years to come, physicians are likely to witness an increase in influx of patients, hence driving the cardiac marker analyzer market.

LumiraDx receives approval for its COVID-19 Antigen Test for use in India

Retrieved on: 
Wednesday, October 20, 2021

The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.

Key Points: 
  • The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.
  • The LumiraDx SARS-CoV-2 Antigen test is a microfluidic test run on the LumiraDx point of care Platform whichscales down, and integrates techniques used in laboratory analyzers to provide lab-comparable diagnostic tests on a single point of care instrument.
  • "Our launch in India with our SARS-CoV-2 Antigen test is an important step forward in this mission.
  • LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.

LumiraDx receives approval for its COVID-19 Antigen Test for use in India

Retrieved on: 
Wednesday, October 20, 2021

LONDON, Oct. 20, 2021 /PRNewswire/ -- Today, LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics testing company announced it has received emergency use approval by India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test for use in India. The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application. In clinical studies, LumiraDx SARS-CoV-2 Antigen test demonstrated a 97.6% positive agreement and 96.6% negative agreement with the PCR test for patients within the first twelve days of symptom, making it one of the fastest, and most sensitive antigen point of care tests currently commercially available. The test has been available in the US and Europe after receiving Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) in August 2020 and having obtained CE Mark in September 2020 respectively.   

Key Points: 
  • LONDON, Oct. 20, 2021 /PRNewswire/ --Today, LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics testing company announced it has received emergency use approval by India'sCentral Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test for use in India.
  • The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.
  • The LumiraDx SARS-CoV-2 Antigen test is a microfluidic test run on the LumiraDx point of care Platform whichscales down, and integrates techniques used in laboratory analyzers to provide lab-comparable diagnostic tests on a single point of care instrument.
  • "Our launch in India with our SARS-CoV-2 Antigen test is an important step forward in this mission.

Western European Cardiac Troponin Diagnostics Market to 2021

Retrieved on: 
Wednesday, June 6, 2018

The "Western European Cardiac Troponin Diagnostics Market, Forecast to 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Western European Cardiac Troponin Diagnostics Market, Forecast to 2021" report has been added to ResearchAndMarkets.com's offering.
  • Cardiac troponins play a key role in minimizing hospital stays and reducing admission rate which are the biggest contributors to overall healthcare expenditure.
  • The WEU cardiac diagnostic market is a high-value market, with a consistent increase in demand due to regulatory changes that are set to impact the cardiac diagnostics market across Europe.
  • The research covers the revenue generated by the use of cardiac troponin tests for diagnosis of acute myocardial infarction.